Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation

Medicina (Kaunas). 2020 Oct 29;56(11):572. doi: 10.3390/medicina56110572.

Abstract

Background and objectives: Streptococcus pneumoniae urinary antigen (u-Ag) testing has recently gained attention in the early diagnosis of severe and critical acute respiratory syndrome coronavirus-2/pneumococcal co-infection. The aim of this study is to assess the effectiveness of Streptococcus pneumoniae u-Ag testing in coronavirus disease 2019 (COVID-19) patients, in order to assess whether pneumococcal co-infection is associated with different mortality rate and hospital stay in these patients.

Materials and methods: Charts, protocols, mortality, and hospitalization data of a consecutive series of COVID-19 patients admitted to a tertiary hospital in northern Italy during COVID-19 outbreak were retrospectively reviewed. All patients underwent Streptococcus pneumoniae u-Ag testing to detect an underlying pneumococcal co-infection. Covid19+/u-Ag+ and Covid19+/u-Ag- patients were compared in terms of overall survival and length of hospital stay using chi-square test and survival analysis.

Results: Out of 575 patients with documented pneumonia, 13% screened positive for the u-Ag test. All u-Ag+ patients underwent treatment with Ceftriaxone and Azithromycin or Levofloxacin. Lopinavir/Ritonavir or Darunavir/Cobicistat were added in 44 patients, and hydroxychloroquine and low-molecular-weight heparin (LMWH) in 47 and 33 patients, respectively. All u-Ag+ patients were hospitalized. Mortality was 15.4% and 25.9% in u-Ag+ and u-Ag- patients, respectively (p = 0.09). Survival analysis showed a better prognosis, albeit not significant, in u-Ag+ patients. Median hospital stay did not differ among groups (10 vs. 9 days, p = 0.71).

Conclusions: The routine use of Streptococcus pneumoniae u-Ag testing helped to better target antibiotic therapy with a final trend of reduction in mortality of u-Ag+ COVID-19 patients having a concomitant pneumococcal infection. Randomized trials on larger cohorts are necessary in order to draw definitive conclusion.

Keywords: COVID-19; SARS-CoV-2; Streptococcus pneumoniae; antibodies; bacterial infection 2.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Anticoagulants / therapeutic use
  • Antigens, Bacterial / urine
  • Antiviral Agents / therapeutic use*
  • Azithromycin / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Ceftriaxone / therapeutic use
  • Cobicistat / therapeutic use
  • Coinfection / diagnosis*
  • Coinfection / urine
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy*
  • Cross-Sectional Studies
  • Darunavir / therapeutic use
  • Drug Combinations
  • Female
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Hospital Mortality*
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Length of Stay / statistics & numerical data
  • Levofloxacin / therapeutic use
  • Lopinavir / therapeutic use
  • Male
  • Mass Screening
  • Middle Aged
  • Pandemics
  • Pneumonia, Pneumococcal / complications
  • Pneumonia, Pneumococcal / diagnosis
  • Pneumonia, Pneumococcal / drug therapy*
  • Pneumonia, Pneumococcal / urine
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Retrospective Studies
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Streptococcus pneumoniae / immunology

Substances

  • Anti-Bacterial Agents
  • Anticoagulants
  • Antigens, Bacterial
  • Antiviral Agents
  • Drug Combinations
  • Heparin, Low-Molecular-Weight
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Levofloxacin
  • Ceftriaxone
  • Azithromycin
  • Cobicistat
  • Ritonavir
  • Darunavir